MW 450.3 Da, Purity >=98%. (S)-crizotinib is a low nanomolar inhibitor of 7,8-dihydro-8-oxoguanine triphosphatase (MTH1 or NUDT1) whereas the (R)-enantiomer shows IC₅₀ values in the micromolar range. MTH1 aids in RAS-transformed cells to overcome oncogene-induced senescence by preventing reactive oxygen species (ROS)-induced DNA damage. The average IC₅₀ values for (S)-crizotinib and the MTH1 substrates 8-oxo-dGTP and 2-OH-dATP is 330 nM and 408 nM respectively. In vitro Kd measurements indicate that (S)-crizotinib is considerably less potent than the (R)-enantiomer against the targets ALK, MET and ROS1. (S)-crizotinib reduces tumor volume by more than 50% in mouse xenograft studies using SW480 cells.
2-hydroxy-dATP diphosphatase, 7 8 dihydro 8 oxoguanine triphosphatase, 8 oxo 7 8 dihydrodeoxyguanosine triphosphatase, 8 oxo 7 8 dihydroguanosine triphosphatase, 8-dihydro-8-oxoguanine triphosphatase, 8-oxo-dGTPase, 8ODP_HUMAN, ALK tyrosine kinase receptor, ALK/EML4 fusion gene, included, ALK/NPM1 fusion gene, included, ALK_HUMAN, AUTS9, Anaplastic lymphoma kinase, Anaplastic lymphoma kinase Ki1, CD 246, CD246 antigen, D249, EC 2.7.10.1, HGF receptor, HGF/SF receptor, HGFR, Hepatocyte growth factor receptor, IF 1, IFG, IFI, IFN immune, IFN-gamma, IFNG_HUMAN, Immune interferon, Interferon gamma, KI 1, MET proto oncogene, receptor tyrosine kinase, MET_HUMAN, Met proto oncogene tyrosine kinase, Met proto-oncogene, Met proto-oncogene (hepatocyte growth factor receptor), MutT human homolog 1, NBLST 3, NUDT 1, Nucleoside diphosphate linked moiety X type motif 1, Nucleoside diphosphate-linked moiety X motif 1, Nudix (nucleoside diphosphate linked moiety X) type motif 1, Nudix hydrolase 1, Nudix motif 1, Nudix type motif 1, Oncogene MET, Proto-oncogene c-Met, RCCP2, SF receptor, Scatter factor receptor, TCRZ, TFG/ALK, Type II Interferon, Tyrosine-protein kinase Met, anaplastic lymphoma kinase (Ki-1), anaplastic lymphoma receptor tyrosine kinase, c met, mutant anaplastic lymphoma kinase
MW 450.3 Da, Purity >=98%. (S)-crizotinib is a low nanomolar inhibitor of 7,8-dihydro-8-oxoguanine triphosphatase (MTH1 or NUDT1) whereas the (R)-enantiomer shows IC₅₀ values in the micromolar range. MTH1 aids in RAS-transformed cells to overcome oncogene-induced senescence by preventing reactive oxygen species (ROS)-induced DNA damage. The average IC₅₀ values for (S)-crizotinib and the MTH1 substrates 8-oxo-dGTP and 2-OH-dATP is 330 nM and 408 nM respectively. In vitro Kd measurements indicate that (S)-crizotinib is considerably less potent than the (R)-enantiomer against the targets ALK, MET and ROS1. (S)-crizotinib reduces tumor volume by more than 50% in mouse xenograft studies using SW480 cells.
~ 5 mg/ml in DMSO (warm if needed).
(S)-crizotinib is a low nanomolar inhibitor of 7,8-dihydro-8-oxoguanine triphosphatase (MTH1 or NUDT1) whereas the (R)-enantiomer shows IC₅₀ values in the micromolar range. MTH1 aids in RAS-transformed cells to overcome oncogene-induced senescence by preventing reactive oxygen species (ROS)-induced DNA damage. The average IC₅₀ values for (S)-crizotinib and the MTH1 substrates 8-oxo-dGTP and 2-OH-dATP is 330 nM and 408 nM respectively. In vitro Kd measurements indicate that (S)-crizotinib is considerably less potent than the (R)-enantiomer against the targets ALK, MET and ROS1. (S)-crizotinib reduces tumor volume by more than 50% in mouse xenograft studies using SW480 cells.
This product is manufactured by BioVision, an Abcam company and was previously called B3071 (S)-Crizotinib. B3071-25 is the same size as the 25 mg size of ab286212.
MTH1 also known as NUDT1 is a protein that hydrolyzes oxidized nucleotides preventing their incorporation into DNA and RNA. It has a mass approximately 23 kDa and is expressed widely with heightened expression in cancer cells where oxidative stress is prevalent. Interferon gamma (IFN-γ) is a cytokine involved in immune responses with a mass of 20 kDa. It is expressed by activated T cells and natural killer cells. ALK or anaplastic lymphoma kinase is a receptor tyrosine kinase with a mass close to 180 kDa mainly expressed in the nervous system and implicated in neural development. Met also known as hepatocyte growth factor receptor (HGFR) or c-Met is another receptor tyrosine kinase with a mass of around 145 kDa and is expressed in various epithelial cells.
MTH1 plays a protective role by clearing oxidized dNTPs safeguarding genomic integrity. It operates mainly as a monomer. Interferon gamma orchestrates immune regulation by activating macrophages and promoting antigen presentation often working as part of a larger cytokine signaling network. Meanwhile ALK transduces signals for cell growth when bound by its ligand through pathways that include MAPK and PI3K. Met upon binding its ligand HGF triggers epithelial cell proliferation and motility acting as a critical player in tissue regeneration and repair.
MTH1 participates in DNA repair pathways interacting with DNA polymerases that mitigate oxidative damage. Interferon gamma engages in the Jak-STAT signaling pathway which influences gene expression related to immune response and inflammation. ALK and Met both integrate into signaling cascades such as the RAS-MAPK and PI3K-Akt pathways often leading to effects on cell cycle progression and survival. These pathways connect ALK and Met with proteins like KRAS and Akt that are vital for cellular responses.
Oxidative DNA damage links MTH1 to various cancers with crizotinib being a related inhibitor showing relevance in treatments targeting oxidative stress. Aberrant signaling involving Interferon gamma correlates with autoimmune conditions like rheumatoid arthritis reflecting its impact on immune-related disorders. ALK becomes significant in specific malignancies like non-small cell lung cancer (NSCLC) where gene rearrangements drive tumorigenesis. Met when dysregulated associates with metastatic cancers with connections to proteins such as HGF that exacerbate tumor invasion and growth.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com